Company / strategic investorRegistered location :San Francisco, CA 94104

Mark N LampertDeclared Swiss shareholdings

Mark N Lampert: 2 Swiss companies with a declared holding, including Molecular Partners AG, Addex Therapeutics Ltd. Latest filing: 24.11.2023.

Disclosure tracking · company alerts with Pro

Estimated value (CHF): …
Swiss companies held: 2
Largest position: 24,13 %; Molecular Partners AG
12-month trend: Not determinable; 0 rate rises · 0 rate falls
Latest filing: 24.11.2023; Active since 2010

Declared Swiss portfolio

Latest declared rate per company

Sector allocation

Share of companies held

Molecular Partners AG

24,13 %24.11.2023

Addex Therapeutics Ltd

2,42 %19.03.2015

How to read these figures?

Rates come from the 23 official filings published by SIX Exchange Regulation. A filing is only required when a threshold is crossed (3, 5, 10, 15, 20, 25, 33⅓, 50, 66⅔%): the actual position may have changed since.

Estimated value = shares held per the latest filing × latest CHF closing price. It is an indicative order of magnitude: the position may have changed without a new threshold being crossed, and holdings without a share count or a CHF price are not valued. Each company's mini-chart traces the successive declared rates.

This profile shows only what the declarant published. No external data is added to it.

Group structure

Shareholding disclosures are often filed jointly by several entities of the same group. The registry links them together: "Controls" lists the group entities declared alongside this shareholder, "Controlled by" the head entities. The figure is the number of joint disclosures, followed by the date of the most recent one.

Show group structure12 controls

Controls

Group entities linked to this shareholder in joint disclosures.

Biotechnology Value Fund, L.P. "BVF"12 · 21.07.2016
Biotechnology Value Fund II, L.P. "BVF2"12 · 21.07.2016
Investment 10, L.L.C. "ILL10"11 · 19.03.2015
BVF Investments, L.L.C. "BVLLC"11 · 19.03.2015
Biotechnology Value Trading Fund OS, L.P11 · 24.11.2023
Biotechnology Value Fund II, L.P11 · 24.11.2023
Biotechnology Value Fund, L.P11 · 24.11.2023
MSI BVF SPV, LLC "MSI"8 · 21.07.2016
BVF Inc8 · 19.03.2015
BVF Partners L.P8 · 19.03.2015
MSI BVF SPV, LLC8 · 24.11.2023
Biotechnology Value Trading Fund OS, L.P. BVFOS1 · 21.07.2016

This mapping reflects observed disclosures; it does not necessarily indicate permanent legal control.

Disclosure behaviour

Upward and downward threshold crossings show direction, without measuring daily trades below legal thresholds.

90 days · Upward crossings

visible history: 21

90 days · Downward crossings

visible history: 0

First disclosure: 16.02.2010Last disclosure: 24.11.2023

Nature of disclosed positions

Derivatives, sale positions or lending may indicate a more complex strategy than a long equity holding.

Equity holdings

Rights / derivatives

Other positions

Declared Swiss portfolio

Sector allocation

Group structure

Controls

Disclosure behaviour

Nature of disclosed positions

Latest shareholding disclosures

Follow Mark N Lampert’s disclosures

Management purchases in this portfolio

Common questions

Explore further

Recent insider purchases

Insider barometer